Option Care Health reported preliminary, unaudited net revenue of $1.46 billion to $1.47 billion for Q4 2025, a year-over-year increase of roughly 8%. On a GAAP basis, the company expects net income of $59.1 million to $62.4 million, or $0.37 to $0.39 per diluted share. Excluding items such as stock-based compensation and acquisition-related expenses, adjusted EPS is projected at $0.46 to $0.49, in line with the prior year’s $0.46. Adjusted EBITDA is estimated at $123.7 million to $127.7 million, up from approximately $113 million a year earlier.

For the full year ended December 31, 2025, Option Care Health anticipates net revenue between $5.645 billion and $5.655 billion, representing roughly 7% growth versus 2024. GAAP net income is expected to land at $208.2 million to $211.5 million, or $1.27 to $1.29 per diluted share. On an adjusted basis, diluted EPS is projected at $1.72 to $1.76, up from $1.65 last year, while adjusted EBITDA is forecast at $469 million to $473 million. Operating cash flow for 2025 is anticipated to be just under $320 million.

Looking ahead, Option Care Health provided preliminary guidance for fiscal 2026, forecasting net revenue of $5.8 billion to $6.0 billion, implying about 3% to 6% top-line growth. Adjusted diluted EPS is guided to a range of $1.82 to $1.92, reflecting continued margin expansion, and adjusted EBITDA is expected between $480 million and $505 million. The company plans to discuss assumptions and drivers in greater detail during its Q4 earnings call scheduled for February.

On January 9, 2026, the board approved an increase in the share buyback program from $500 million to $1 billion with no expiration date. During Q4 2025, the company repurchased $95 million of shares and $307 million for the full year, leaving $193 million of capacity under the original plan. The additional $500 million authorization underscores management’s confidence in free cash flow generation and long-term value creation.